Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access.
donor-derived infections
donors and donation
hepatitis C
infection and infectious agents
kidney disease
viral
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
20
12
2019
revised:
06
02
2020
accepted:
13
02
2020
pubmed:
20
2
2020
medline:
24
6
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
The advent of direct-acting antivirals (DAAs) has provided the impetus to transplant kidneys from hepatitis C virus-positive donors into uninfected recipients (D+/R-). Thirty D+/R- patients received DAA treatment. Sustained virologic response (SVR12) was defined as an undetectable viral load in 12 weeks after treatment. An age-matched cohort of uninfected donor and recipient pairs (D-/R-) transplanted during same time period was used for comparison. The median day of viral detection was postoperative day (POD) 2. The detection of viremia in D+/R- patients was 100%. The initial median viral load was 531 copies/μL (range: 10-1 × 10
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13833Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Querard A-H, Foucher Y, Combescure C, et al. Comparison of survival outcomes between Expanded Criteria Donor and Standard Criteria Donor kidney transplant recipients: a systematic review and meta-analysis. Transpl Int. 2016;29(4):403-415.
Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252-259.
Torabi J, Graham JA, Choinski K, et al. Young donors with severe acute kidney injury offer an opportunity to expand the donor pool. Am J Surg. 2019;218(1):7-13.
Colovai AI, Ajaimy M, Kamal LG, et al. Increased access to transplantation of highly sensitized patients under the new kidney allocation system. A single center experience. Human Immunol. 2017;78(3):257-262.
Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533-540.
Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394-2395.
Chute DF, Chung RT, Sise ME. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. Kidney Int. 2018;93(3):560-567.
Colombo M, Aghemo A, Liu H, et al. Treatment with Ledipasvir-Sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166(2):109-117.
Bhamidimarri KR, Ladino M, Pedraza F, et al. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. Transpl Int. 2017;30(9):865-873.
Durand CM, Bowring MG, Thomas AG, et al. The drug overdose epidemic and deceased-donor transplantation in the United States: A National Registry Study. Ann Intern Med. 2018;168(10):702-711.
Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411-1419.
Sibulesky L, Kling CE, Blosser C, et al. Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider. Am J Transplant. 2018;18(10):2465-2472.
Sawinski D, Wyatt CM, Locke JE. Expanding the use of hepatitis C-viremic kidney donors. Kidney Int. 2017;92(5):1031-1033.
Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C-positive kidneys. N Engl J Med. 2015;373(4):303-305.
Chute DF, Sise ME. Effect of the Opioid crisis on the donor pool for kidney transplantation: an analysis of national kidney deceased donor trends from 2010-2016. Am J Nephrol. 2018;47(2):84-93.
Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10(5):1238-1246.
Bowring MG, Holscher CM, Zhou S, et al. Turn down for what? Patient outcomes associated with declining increased infectious risk kidneys. Am J Transplant. 2018;18(3):617-624.
Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of HCV antibody-positive deceased donor kidneys in the era of direct-acting antiviral therapy. Transplantation. 2018;102(12):2088-2095.
Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99(6):1192-1196.
de Vera ME, Volk ML, Ncube Z, et al. Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia. Am J Transplant. 2018;18(10):2451-2456.
Agarwal N, Davis RJ, Gracey DM, et al. Detection of hepatitis C antibodies without viral transmission in hepatitis C-negative recipients receiving kidneys from hepatitis C-positive donors treated with direct-acting antiviral therapy. Transplantation. 2018;102(3):e121-e122.
Heinrichs A, Antoine M, Steensels D, Montesinos I, Delforge ML. HCV false positive immunoassays in patients with LVAD: A potential trap! J Clin Virol. 2016;78:44-46.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl. 1):S35-S46.
Sibulesky L, Limaye AP. NAT testing in recipients of hepatitis C aviremic donor organs. Am J Transplant. 2018;18(4):1030-1030.
Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790-2802.
Wolfe CR, Michaels MG. Donor-derived hepatitis C transmission from NAT negative donors-Still an unexpected event! Am J Transplant. 2017; 17(11):2989.
Potluri VS, Goldberg DS, Mohan S, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. J Am Soc Nephrol. 2019;30(10):1939-1951.
Schlendorf KH, Zalawadiya S, Shah AS, et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. J Heart Lung Transplant. 2018;37(6):763-769.
Kwong AJ, Wall A, Melcher M, et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant. 2019;19(5):1380-1387.
Bari K, Luckett K, Kaiser T, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018;67(5):1673-1682.
McLean RC, Reese PP, Acker M, et al. Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial. Am J Transplant. 2019;19(9):2533-2542.
Gallegos-Orozco JF, Kim R, Thiesset HF, et al. Early results of pilot study using hepatitis C virus (HCV) positive kidneys to transplant HCV infected patients with end-stage renal disease allowing for successful interferon-free direct acting antiviral therapy after transplantation. Cureus. 2016;8(11):e890.
Lubetzky M, Chun S, Joelson A, et al. Safety and efficacy of treatment of hepatitis c in kidney transplant recipients with directly acting antiviral agents. Transplantation. 2017;101(7):1704-1710.
Reddy S, Sharma RK, Mehrotra S, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Clin Kidney J. 2018;11(3):429-433.
Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology. 2017;66(4):1090-1101.
Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16(5):1588-1595.
Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. Am J Transplant. 2019;19(11):3046-3057.
Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88(2):231-236.
Graham JA, Ajaimy M, Carrero J, et al. Hepatitis C virus positivity should not be included in the kidney donor profile index calculation when transplanting HCV-positive kidneys into noninfected recipients in the era of direct-acting antiviral agents. Prog Transplant. 2019;29(4):371-372.